CoChat
Sign Up
Cited by 203Amyotrophic Lateral Sclerosis ResearchNeuroinflammation and Neurodegeneration MechanismsAdvanced Glycation End Products research

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue

Casula, M., Iyer, A.M., Spliet, W.G.M., Anink, J.J., Steentjes, K., Sta, M., Troost, D., Aronica, E.·2011·Neuroscience
DOI 10.1016/j.neuroscience.2011.02.001
Open this paper in CoChat — free account

Abstract

Increasing evidence indicates that inflammatory responses could play a critical role in the pathogenesis of motor neuron injury in amyotrophic lateral sclerosis (ALS). Recent findings have underlined the role of Toll-like receptors (TLRs) and the receptor for advanced glycation endproducts (RAGE) in the regulation of both innate and adaptive immunity in different pathologies associated with neuroinflammation. In the present study we investigated the expression and cellular distribution of TLR2, TLR4, RAGE and their endogenous ligand high mobility group box 1 (HMGB1) in the spinal cord of control (n=6) and sporadic ALS (n=12) patients. The immunohistochemical analysis of TLR2, TLR4 and RAGE showed increased expression in reactive glial cells in both gray (ventral horn) and white matter of ALS spinal cord. TLR2 was predominantly detected in cells of the microglia/macrophage lineage, whereas the TLR4 and RAGE was strongly expressed in astrocytes. Real-time quantitative PCR analysis confirmed the increased expression of both TLR2 and TLR4 and HMGB1 mRNA level in ALS patients. In ALS spinal cord, HMGB1 signal is increased in the cytoplasm of reactive glia, indicating a possible release of this molecule from glial cells. Our findings show increased expression of TLR2, TLR4, RAGE and HMGB1 in reactive glia in human ALS spinal cord, suggesting activation of the TLR/RAGE signaling pathways. The activation of these pathways may contribute to the progression of inflammation, resulting in motor neuron injury. In this context, future studies, using animal models, will be important to achieve a better understanding of these signaling pathways in ALS in view of the development of new therapeutic strategies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuroscience.2011.02.001

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Cited by

Sorted by citations

See all 203

Related

Metadata

Authors
Casula, M., Iyer, A. M., Spliet, W. G. M., Anink, J. J., Steentjes, K., Sta, M., Troost, D., & Aronica, E.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University Medical Center Utrecht (NL)
Corresponding author
Aronica, E.
ORCID
Venue
Neuroscience
Publisher
Elsevier BV
Published
2011-04
Volume
179
Pages
233-243
ISSN
0306-4522 (ISSN-L)
DOI
10.1016/j.neuroscience.2011.02.001
OpenAlex
W2069842601
Cited by
200
References
56
Citations by year
2026: 7 · 2025: 7 · 2024: 13 · 2023: 8 · 2022: 15 · 2021: 16 · 2020: 9 · 2019: 8 · 2018: 21 · 2017: 28 · 2016: 11 · 2015: 19 · 2014: 13 · 2013: 13 · 2012: 10
FWCI
7.72
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
amyotrophic lateral sclerosis, TLR2, TLR4, receptor for advanced glycation end products, high mobility group box 1, neuroinflammation, reactive glia, microglia/macrophages, astrocytes, motor neuron injury, spinal cord, ventral horn
MeSH terms
Receptor for Advanced Glycation End Products, Aged, Aged, 80 and over, Amyotrophic Lateral Sclerosis, Astrocytes, Female, Humans, Immunohistochemistry, Male, Middle Aged, Spinal Cord, Signal Transduction, In Situ Hybridization, Reverse Transcriptase Polymerase Chain Reaction, HMGB1 Protein, Toll-Like Receptor 2, Toll-Like Receptor 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review